John Rogers's CRL Position Overview
John Rogers (via Ariel Investments, LLC) currently holds 1.43 M shares of Charles River Laboratories International, Inc. (CRL) worth $284.81 M, representing 3.08% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, John Rogers has maintained a long-term strategic position in CRL, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2017, adding 483,564 shares. Largest reduction occurred in Q1 2014, reducing 619,955 shares.
Analysis based on 13F filings available since 2013 Q2
John Rogers's Charles River Laboratories International (CRL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Charles River Laboratories International (CRL) Trades by John Rogers
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -62,327 | Reduce 4.18% | 1.43 M | $199.48 |
| Q3 2025 | +74,750 | Add 5.28% | 1.49 M | $156.46 |
| Q2 2025 | +314,572 | Add 28.58% | 1.42 M | $151.73 |
| Q1 2025 | +33,449 | Add 3.13% | 1.1 M | $150.52 |
| Q4 2024 | +169,640 | Add 18.90% | 1.07 M | $184.60 |
| Q3 2024 | -8,450 | Reduce 0.93% | 897,687 | $196.97 |
| Q2 2024 | -26,670 | Reduce 2.86% | 906,137 | $206.58 |
| Q1 2024 | -117,891 | Reduce 11.22% | 932,807 | $270.95 |
| Q4 2023 | -15,902 | Reduce 1.49% | 1.05 M | $236.40 |
| Q3 2023 | +18,760 | Add 1.79% | 1.07 M | $195.98 |
| Q2 2023 | +364,786 | Add 53.41% | 1.05 M | $210.25 |
| Q1 2023 | +45,292 | Add 7.10% | 683,054 | $201.82 |
| Q4 2022 | -12,736 | Reduce 1.96% | 637,762 | $217.90 |
| Q3 2022 | +60,859 | Add 10.32% | 650,498 | $196.80 |
| Q2 2022 | +379,844 | Add 181.05% | 589,639 | $213.97 |
| Q1 2022 | +30,148 | Add 16.78% | 209,795 | $283.97 |
| Q4 2021 | -3,558 | Reduce 1.94% | 179,647 | $376.78 |
| Q3 2021 | -37,894 | Reduce 17.14% | 183,205 | $412.67 |
| Q2 2021 | -189,974 | Reduce 46.21% | 221,099 | $369.92 |
| Q1 2021 | -1,793 | Reduce 0.43% | 411,073 | $289.83 |
| Q4 2020 | -77,476 | Reduce 15.80% | 412,866 | $249.86 |
| Q3 2020 | -134,264 | Reduce 21.50% | 490,342 | $226.45 |
| Q2 2020 | -60,977 | Reduce 8.89% | 624,606 | $174.35 |
| Q1 2020 | -164,511 | Reduce 19.35% | 685,583 | $126.21 |
| Q4 2019 | +8,497 | Add 1.01% | 850,094 | $152.76 |
| Q3 2019 | +26,090 | Add 3.20% | 841,597 | $132.37 |
| Q2 2019 | -30,935 | Reduce 3.65% | 815,507 | $141.90 |
| Q1 2019 | -141,729 | Reduce 14.34% | 846,442 | $145.25 |
| Q4 2018 | -265,795 | Reduce 21.20% | 988,171 | $113.18 |
| Q3 2018 | -63,620 | Reduce 4.83% | 1.25 M | $134.54 |
| Q2 2018 | -43,691 | Reduce 3.21% | 1.32 M | $112.26 |
| Q1 2018 | +8,082 | Add 0.60% | 1.36 M | $106.74 |
| Q4 2017 | -326,871 | Reduce 19.46% | 1.35 M | $109.45 |
| Q3 2017 | -270,301 | Reduce 13.86% | 1.68 M | $108.02 |
| Q2 2017 | -110,053 | Reduce 5.34% | 1.95 M | $101.15 |
| Q1 2017 | +483,564 | Add 30.67% | 2.06 M | $89.95 |
| Q4 2016 | +150,014 | Add 10.51% | 1.58 M | $76.19 |
| Q3 2016 | -37,288 | Reduce 2.55% | 1.43 M | $83.34 |
| Q2 2016 | -202,825 | Reduce 12.17% | 1.46 M | $82.44 |
| Q1 2016 | -75,935 | Reduce 4.36% | 1.67 M | $75.94 |
| Q4 2015 | +68,560 | Add 4.09% | 1.74 M | $80.39 |
| Q3 2015 | -5,320 | Reduce 0.32% | 1.67 M | $63.52 |
| Q2 2015 | -78,795 | Reduce 4.48% | 1.68 M | $70.34 |
| Q1 2015 | -245,610 | Reduce 12.26% | 1.76 M | $79.29 |
| Q4 2014 | +7,785 | Add 0.39% | 2 M | $63.64 |
| Q3 2014 | +45,613 | Add 2.34% | 2 M | $59.74 |
| Q2 2014 | -58,605 | Reduce 2.92% | 1.95 M | $53.52 |
| Q1 2014 | -619,955 | Reduce 23.58% | 2.01 M | $60.34 |
| Q4 2013 | -120,688 | Reduce 4.39% | 2.63 M | $53.04 |
| Q3 2013 | +15,455 | Add 0.57% | 2.75 M | $46.26 |
| Q2 2013 | +2.73 M | Add 0.00% | 2.73 M | $41.03 |
John Rogers's Charles River Laboratories International Investment FAQs
John Rogers first purchased Charles River Laboratories International, Inc. (CRL) in Q2 2013, acquiring 2,734,450 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Rogers has held Charles River Laboratories International, Inc. (CRL) for 51 quarters since Q2 2013.
John Rogers's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q2 2013, adding 2,734,450 shares worth $112.19 M.
According to the latest 13F filing for Q4 2025, John Rogers's firm, Ariel Investments, LLC, owns 1,427,771 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $284.81 M.
As of the Q4 2025 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 3.08% of John Rogers's publicly disclosed stock portfolio, making it one of their key holdings.
John Rogers's peak holding in Charles River Laboratories International, Inc. (CRL) was 2,749,905 shares, as reported at the end of Q3 2013.